Tax-related sell-to-cover by SOPHiA GENETICS (SOPH) Chief Sales Officer

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small, non-discretionary share sale tied to taxes. On April 18, 2026, 33 Ordinary Shares were sold in the open market at an average price of $5.0816 per share to satisfy tax obligations from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 148,197 Ordinary Shares.

Insider Trade Summary

Net Seller: 33 shares ($168)

Net Sell 1 txn

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 33 shs ($167.69)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	33	$5.0816	$167.69

Holdings After Transaction: Ordinary Shares — 148,197 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 33 shares Sale price per share: $5.0816 per share Shares owned after transaction: 148,197 shares

3 metrics

Shares sold 33 shares Ordinary Shares sold on April 18, 2026

Sale price per share $5.0816 per share Open-market sale to satisfy tax obligations

Shares owned after transaction 148,197 shares Direct ownership following tax-related sale

Key Terms

restricted stock units, sell to cover, open market, non-discretionary trades

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units on April 18, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"The sales were effected as a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

open market financial

"Represents shares sold by the Reporting Person in the open market"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

non-discretionary trades financial

"do not represent discretionary trades"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/20/2026		S		33(1)	D	$5.0816	148,197	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) executive Kevin Puylaert report in this Form 4?

Kevin Puylaert reported a small sale of 33 SOPHiA GENETICS Ordinary Shares. The shares were sold in the open market solely to cover tax obligations arising from vesting restricted stock units, and the transaction was not a discretionary trade or portfolio decision.

Was the SOPH insider share sale by Kevin Puylaert a discretionary trade?

No, the Form 4 states the sale did not represent discretionary trades. The 33 shares were sold as a “sell to cover” transaction specifically to satisfy tax obligations triggered by restricted stock units vesting, rather than an active decision to reduce his investment position.

How many SOPHiA GENETICS shares did Kevin Puylaert sell and at what price?

Kevin Puylaert sold 33 Ordinary Shares of SOPHiA GENETICS. The filing reports an average sale price of $5.0816 per share in an open-market transaction conducted to cover taxes related to recently vested restricted stock units awarded as part of his compensation.

How many SOPHiA GENETICS shares does Kevin Puylaert own after this Form 4 transaction?

After the reported sale, Kevin Puylaert directly holds 148,197 Ordinary Shares. This indicates the tax-related sale of 33 shares was very small compared with his remaining position, and his overall direct ownership in SOPHiA GENETICS remains largely unchanged by this filing.

What is a 'sell to cover' transaction in the SOPH Form 4 filing?

A “sell to cover” transaction is when shares are sold to pay taxes owed on vested equity awards. In this case, 33 SOPHiA GENETICS Ordinary Shares were sold to satisfy tax obligations from restricted stock units vesting, rather than as a discretionary investment or trading decision.